Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression

被引:71
作者
Elser, Michael [1 ]
Borsig, Lubor [2 ]
Hassa, Paul O. [4 ]
Erener, Suheda [1 ]
Messner, Simon [1 ]
Valovka, Taras [1 ]
Keller, Stephan [3 ]
Gassmann, Max [3 ]
Hottiger, Michael O. [1 ]
机构
[1] Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland
[2] Univ Zurich, Zurich Ctr Interat Human Physiol ZIHP, Inst Physiol, CH-8057 Zurich, Switzerland
[3] Univ Zurich, Zurich Ctr Interat Human Physiol ZIHP, Inst Vet Physiol, CH-8057 Zurich, Switzerland
[4] EMBL, Gene Express Unit, Heidelberg, Germany
关键词
D O I
10.1158/1541-7786.MCR-07-0377
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hypoxia-inducible factor 1 (HIF-1) is the key transcription factor regulating hypoxia-dependent gene expression. Lack of oxygen stabilizes HIF-1, which in turn modulates the gene expression pattern to adapt cells to the hypoxic environment. Activation of HIF-1 is also detected in most solid tumors and supports tumor growth through the expression of target genes that are involved in processes like cell proliferation, energy metabolism, and oxygen delivery. Poly(ADP-ribose) polymerase 1 (PARP1) is a chromatin-associated protein, which was shown to regulate transcription. Here we report that chronic myelogenous leukemia cells expressing small interfering RNA against PARP1, which were injected into wild-type mice expressing PARP1, showed tumor growth with increased levels of necrosis, limited vascularization, and reduced expression of GLUT-1. Of note, PARP-1-deficient cells showed a reduced HIF-1 transcriptional activation that was dependent on PARP1 enzymatic activity. PARP1 neither influenced binding of HIF-1 to its hypoxic response element nor changed HIF-1 alpha protein levels in hypoxic cells. However, PARP1 formed a complex with HIF-1 alpha through direct protein interaction and coactivated HIF-1 alpha-dependent gene expression. These findings provide convincing evidence that wild-type mice expressing PARP1 cannot compensate for the loss of PARP1 in tumor cells and strengthen the importance of the role of PARP1 as a transcriptional coactivator of HIF-1-dependent gene expression during tumor progression.
引用
收藏
页码:282 / 290
页数:9
相关论文
共 53 条
[1]  
Airley R, 2001, CLIN CANCER RES, V7, P928
[2]   SYMPOSIUM - CELLULAR-RESPONSE TO DNA DAMAGE - THE ROLE OF POLY(ADP-RIBOSE) - POLY(ADP-RIBOSE) IN THE CELLULAR-RESPONSE TO DNA DAMAGE [J].
BERGER, NA .
RADIATION RESEARCH, 1985, 101 (01) :4-15
[3]   The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling [J].
Berra, E ;
Ginouvès, A ;
Pouysségur, J .
EMBO REPORTS, 2006, 7 (01) :41-45
[4]   Signalling via the hypoxia-inducible factor-1α requires multiple posttranslational mofications [J].
Brahimi-Horn, C ;
Mazure, N ;
Pouysségur, J .
CELLULAR SIGNALLING, 2005, 17 (01) :1-9
[5]   Induction of an interferon response by RNAi vectors in mammalian cells [J].
Bridge, AJ ;
Pebernard, S ;
Ducraux, A ;
Nicoulaz, AL ;
Iggo, R .
NATURE GENETICS, 2003, 34 (03) :263-264
[6]   Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].
Bryant, HE ;
Schultz, N ;
Thomas, HD ;
Parker, KM ;
Flower, D ;
Lopez, E ;
Kyle, S ;
Meuth, M ;
Curtin, NJ ;
Helleday, T .
NATURE, 2005, 434 (7035) :913-917
[7]   Attenuation of HIF-1 DNA-binding activity limits hypoxia-inducible endothelin-1 expression [J].
Camenisch, G ;
Stroka, DM ;
Gassmann, M ;
Wenger, RH .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2001, 443 (02) :240-249
[8]   Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice [J].
Conde, C ;
Mark, M ;
Oliver, FJ ;
Huber, A ;
de Murcia, G ;
Ménissier-de Murcia, J .
EMBO JOURNAL, 2001, 20 (13) :3535-3543
[9]   Effect of poly(ADP-ribose) polymerase inhibitors on oxidative stress evoked hydroxyl radical level and macromolecules oxidation in cell free system of rat brain cortex [J].
Czapski, GA ;
Cakala, M ;
Kopczuk, D ;
Strosznajder, JB .
NEUROSCIENCE LETTERS, 2004, 356 (01) :45-48
[10]  
Donovan CE, 1999, J IMMUNOL, V163, P6827